

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001258

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
 - a. type of material
 - ☒ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material
 - ☒ on paper
 - ☒ in electronic form
 - c. time of filing/furnishing
 - ☒ contained in the international application as filed.
 - ☒ filed together with the international application in electronic form.
 - ☐ furnished subsequently to this Authority for the purposes of search.
2. ☐ In addition, in the case that more than one version or copy of a sequence, listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments :

International application No.
PCT/CA2005/001258

IPC(7): C12N 15/11, C07H 21/02, A61P 35/04, A61K 31/7105, A61K 48/00

According to International Patent Classification (IPC) or to both national classification and IPC

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C12N 15/11, C07H 21/02, A61P 35/04, A61K 31/7105, A61K 48/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
STN (Biosis, Caplus, Medline), WEST, Delphion, GenomeQuest (searches of SEQ ID NOs: 423-435, odd numbers), Canadian Patent
Database; keywords: "ribonucleotide reductase", "siRNA", RNA interference

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO98/05769 A2 (GENESENSE TECHNOLOGIES, INC (CA)) 12 February 1998	1-8, 11-26, 29, 31-39
Y	- page 7, lines 6-19; page 12, lines 1-page 13, line 16; Tables 7, 11 - cited in the application	9, 10, 27, 28, 30
X	WO00/47733 A1 (GENESENSE TECHNOLOGIES, INC (CA)) 17 August 2000	1-8, 11-26, 29, 31-39
Y	- page 20, lines 3-14; page 53, lines 5- 24; Tables 1-3 - cited in the application	9, 10, 27, 28, 30
X	PING LIN, Z. et al. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. Journal of Biological Chemistry, 25 June 2004, Volume 279, No. 26, pages 27030-27038, ISSN 0021-9258.	1-10, 12, 17-28, 30-33
A	- the entire document	11, 13-16, 29, 34-39

☒ Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

¹⁷ Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"A" document defining the general state of the art which is not considered to be of particular relevance

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.

⁵ earlier application or patent but published on or after the international filing date

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

¹⁶ *Id.* document member of the same patent family

¹¹O document referring to an oral disclosure, use, exhibition or other means.

² document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

Date of mailing of the international search report

19 December 2005 (19-12-2005)

03 January 2006 (03-01-2006)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 001(819)953-2476

Authorized officer

Michael W. De Vouge (819) 997-2952

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2005/001258

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	STRAUSBERG, R.L. et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. GenBank nucleotide sequence database. Bethesda, MD: National Center for Biotechnology Information, 29 June 2004 [retrieved on 13 December 2005]. Retrieved from the Internet: <URL: http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=12804874 >, accession no. BC01886.	1, 2, 6-10, 17-20, 24-28, 30
A		3-5, 11-16, 21-23, 29, 31-39
Y	DUXBURY, M.S. et al. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene, February 2004, Volume 23, No. 8, pages 1539-1548, ISSN 0950-9232.	1, 2, 6-10, 17-20, 24-28, 30
A	-cited in the application	3-5, 11-16, 21-23, 29, 31-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.
PCT/CA2005/001258

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO9805769 A2	12-02-1998	AU738592 B2	20-09-2001
		AU3617597 A	23-02-1998
		CA2262776 A1	12-02-1998
		CN1189562C C	16-02-2005
		EP0917569 A2	26-05-1999
		IL128124D D0	30-11-1999
		JP2000517167T T	26-12-2000
		NZ333802 A	28-09-2001
		US5998383 A	07-12-1999
		US6593305 B1	15-07-2003
		US2004009948 A1	15-01-2004
		AT 309345T	15-11-2005
WO0047733 A1	17-08-2000	AU780455 B2	24-03-2005
		AU2529200 A	29-08-2000
		BR0008788 A	06-11-2001
		CA2366487 A1	17-08-2000
		CN1345373 A	17-04-2002
		EP1153128 A1	14-11-2001
		IL144727D D0	30-06-2002
		JP2003500006T T	07-01-2003
		NZ514090 A	28-01-2005
		US6121000 A	19-09-2000
		AT 309346T	15-11-2005